novel non-purine xanthine oxidase inhibitor

LG Chem Announces Topline Results of LC350189 From the Phase 2 Study (CLUE Study) Promising to Be a New Treatment Alternative With Improved Efficacy and Safety Profiles for Chronic Gout Patients

Seoul, South Korea & Cambridge, Mass., United States:  LC350189 showed significant serum uric acid (sUA)-lowering effects across all dose levels.…

Read More »